Ebola virus: Silent transmission and a deadly biological storm
Keywords: Ebola virus, Filoviridae, infectious disease, disease mortality
Overview of ebola virus disease
Ebola virus disease (EVD) is an acute infectious disease characterized by a high fatality rate and a strong potential to cause outbreaks, particularly in regions with limited healthcare infrastructure. The causative agent is the Ebola virus, a negative-sense single-stranded RNA virus belonging to the Filoviridae family, with a characteristic filamentous structure. The disease was first identified in 1976 during two simultaneous outbreaks in Sudan and the Democratic Republic of the Congo, near the Ebola River, from which the disease derives its name.
A key feature of Ebola is its ability to cause multi-organ damage, particularly affecting the immune system and vascular system. Although commonly associated with hemorrhagic manifestations, not all patients exhibit bleeding symptoms, which can make early clinical recognition more challenging.
Origin and transmission mechanisms
Ebola is a zoonotic disease, with fruit bats considered the primary natural reservoir of the virus. Transmission from animals to humans can occur through direct contact with blood, secretions, or tissues of infected animals, especially during hunting or the preparation of bushmeat.
Once introduced into the human population, Ebola spreads primarily through direct contact with bodily fluids of infected individuals or deceased patients. These fluids include blood, saliva, sweat, urine, feces, breast milk, and semen. Additionally, the virus can persist on contaminated surfaces or objects, leading to indirect transmission.
Importantly, the transmission risk of Ebola is highly dependent on close contact. In healthcare settings, inadequate infection control measures can facilitate rapid spread between patients and healthcare workers.
Origin and transmission mechanisms of Ebola virus disease.
Clinical manifestations
The incubation period of Ebola ranges from 2 to 21 days, with an average of 8–10 days. The initial phase is typically nonspecific, presenting with symptoms such as sudden onset of fever, fatigue, muscle pain, headache, and sore throat. These features often resemble other common infectious diseases in tropical regions, such as malaria or dengue fever.
As the disease progresses, patients may develop gastrointestinal symptoms, including severe vomiting and diarrhea, leading to dehydration and electrolyte imbalance. Liver and kidney functions may also become impaired. In severe cases, coagulation abnormalities can occur, resulting in internal and external bleeding, such as gum bleeding or subcutaneous hemorrhage.
The clinical course is often rapid and severe, with a high risk of shock, multi-organ failure, and death if not promptly managed.
Diagnosis
Early diagnosis of Ebola is particularly challenging due to its nonspecific clinical presentation and similarity to other infectious diseases. Therefore, epidemiological factors—such as recent travel to endemic areas or contact with suspected cases—play a crucial role in guiding clinical suspicion.
Laboratory testing remains the gold standard for confirmation. Common diagnostic methods include reverse transcription polymerase chain reaction (RT-PCR) to detect viral RNA, enzyme-linked immunosorbent assay (ELISA) to identify antigens or antibodies, and, in some cases, viral isolation. These procedures must be conducted in high-containment laboratories (biosafety level 4, BSL-4) due to the high risk of infection.
Treatment and clinical management
Currently, the management of Ebola primarily relies on supportive care aimed at maintaining vital functions and preventing complications. Fluid and electrolyte replacement is critical, particularly in patients experiencing severe dehydration due to vomiting and diarrhea. Additional supportive measures include maintaining blood pressure, providing oxygen therapy, and treating secondary infections when present.
In recent years, targeted therapies such as monoclonal antibodies have been developed and shown to improve survival rates, especially when administered early in the course of the disease. This represents a significant advancement in Ebola treatment, which was previously limited to supportive care alone.
Early detection and intensive supportive care remain key factors in reducing mortality.
Prevention and control
Prevention of Ebola focuses on interrupting transmission within communities and healthcare settings. This includes avoiding contact with potentially infected wildlife, particularly bats and non-human primates, as well as ensuring safe handling and preparation of animal products.
In healthcare environments, strict adherence to infection prevention and control measures is essential. This involves the proper use of personal protective equipment (PPE), sterilization of medical instruments, and isolation of infected patients. Additionally, safe and controlled burial practices are crucial, as the bodies of deceased patients remain highly infectious.
Ebola vaccines, particularly the rVSV-ZEBOV vaccine, have been successfully deployed in recent outbreaks, significantly contributing to disease control. Strategies such as ring vaccination have proven effective in limiting the spread of the virus.
Prevention and control measures for Ebola virus disease.
Interesting aspects and medical significance
One notable feature of Ebola is the virus’s ability to persist in so-called immune-privileged sites, such as the testes, eyes, and central nervous system, even after clinical recovery. This persistence explains the occurrence of delayed transmission in some cases, particularly through sexual contact.
Furthermore, Ebola serves as a critical example of the importance of public health systems and epidemiological surveillance. Large-scale outbreaks, such as the West African epidemic from 2014 to 2016, have highlighted the necessity of international cooperation in controlling infectious diseases.
From a research perspective, Ebola has played a pivotal role in advancing vaccine development and immunotherapy, particularly monoclonal antibody technologies, which may have broader applications in treating other emerging infectious diseases.
References:
- Hollingshead, C. M., Swinkels, H. M., & Shah, S. U. (2024, March 1). Ebola virus disease. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK560579/
- World Health Organization. (2025, April 24). Ebola disease. https://www.who.int/news-room/fact-sheets/detail/ebola-disease